Tenofovir Disoproxil Aspartate

天冬氨酸替诺福韦酯

Report date: 2026/01/06 13:25:21

Base Information

Drug NameTenofovir Disoproxil Aspartate
Drug Alias Name替诺福韦酯天冬氨酸TenofobellCKD-390
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHBV DNA Polymerase inhibitors
TargetsReverse transcriptaseHBV DNA Polymerase
Therapy Area/IndicationsHepatitis B, ChronicHIV Infections
Global Approved IndicationsHepatitis B, Chronic
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2017/08/11
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesChong Kun Dang Pharmaceutical Corp
China Registration ClassN/A

Develop Information

Active CompaniesChong Kun Dang Pharmaceutical Corp
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsHepatitis B, Chronic
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A